The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1233
In Brief: Telithromycin Hepatotoxicity
Download PDF:   US English
Med Lett Drugs Ther. 2006 Apr 24;48(1233):33
Disclosures
Objective(s)
 Select a term to see related articles  1233   2006   Acute bacterial sinusitis   Antibiotics   Antimicrobials   april 2006   april 24   Bronchitis   Community acquired pneumonia   Community-acquired pneumonia   drugs of choice   hepatotoxicity   issue 1233   Ketek   Telithromycin   telithromycin hepatotoxicity   vol 48   vol. 48   volume 48 

Telithromycin (Ketek) is an oral erythromycin derivative FDA-approved for treatment of mild to moderate community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial sinusitis (Med Lett Drugs Ther 2004; 46:66). It is generally considered an alternative antibiotic because of its cost, potential for adverse effects including visual disturbances, exacerbation of myasthenia gravis, hepatotoxicity and drug interactions. A recent report (Ann Intern Med 2006; 144:415) described serious hepatotoxicity probably related to telithromycin in three patients, including one who died and another who needed a liver transplant. Many other oral antibiotics are available for treatment of community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial sinusitis in adults (Med Lett Drugs Ther 2005; 47:78).

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article